Joint Use of Rabbit ATG and Posttransplant Immunosuppression with Cyclophosphamide for HLA-Matched Peripheral Blood Hematopoietic Cell Transplantation, a Calcineurin Inhibitor-Free Graft-Versus-Host Disease Prophylaxis – the NCT06299462 Jurassic Phase I/II Trial (TCT-ASTCT-CIBMTR 2026) - Jan 8, 2026 - Abstract #352; 246; Pres time: Feb 5, 2026; 06:30 PM - 08:00 PM; Location: Hall AB (Salt Palace Convention Center); P1/2 | "One patient with measurable residual disease had steroid-refractory cGVHD and is on sirolimus...No patient received letermovir...2023. PMID: 37140099 Calcineurin inhibitor-free GVHD prophylaxis for HLA-matched PBSC donors with ATG and PTCy is feasible Although CMV reactivation appears to be high, there was no case of CMV disease CRS following graft infusion seems high"
P1/2 data • Post-transplantation • Preclinical • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatology • Hodgkin Lymphoma • Immunology • Leukemia • Liver Failure • Lymphoma • Myelodysplastic Syndrome • Thrombosis • Transplantation
|
|
Leonardo Arcuri; Andreza Ribeiro; Simone Lermontov; Simone Maradei; Mariana Roque; Carla Ribeiro
|